Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1995 Jun;95(6):2425–2426. doi: 10.1172/JCI117938

Amphotropic but not atherotropic: another caveat for adenoviral gene therapy.

W Casscells, J T Willerson
PMCID: PMC295908  PMID: 7769084

Full text

PDF
2426

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biro S., Yu Z. X., Fu Y. M., Smale G., Sasse J., Sanchez J., Ferrans V. J., Casscells W. Expression and subcellular distribution of basic fibroblast growth factor are regulated during migration of endothelial cells. Circ Res. 1994 Mar;74(3):485–494. doi: 10.1161/01.res.74.3.485. [DOI] [PubMed] [Google Scholar]
  2. Casscells W., Lappi D. A., Olwin B. B., Wai C., Siegman M., Speir E. H., Sasse J., Baird A. Elimination of smooth muscle cells in experimental restenosis: targeting of fibroblast growth factor receptors. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7159–7163. doi: 10.1073/pnas.89.15.7159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Casscells W., Willerson J. T. Amphotropic but not atherotropic: another caveat for adenoviral gene therapy. J Clin Invest. 1995 Jun;95(6):2425–2426. doi: 10.1172/JCI117938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chen J., Gamou S., Takayanagi A., Shimizu N. A novel gene delivery system using EGF receptor-mediated endocytosis. FEBS Lett. 1994 Jan 31;338(2):167–169. doi: 10.1016/0014-5793(94)80357-9. [DOI] [PubMed] [Google Scholar]
  5. Flugelman M. Y., Jaklitsch M. T., Newman K. D., Casscells W., Bratthauer G. L., Dichek D. A. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation. 1992 Mar;85(3):1110–1117. doi: 10.1161/01.cir.85.3.1110. [DOI] [PubMed] [Google Scholar]
  6. French Anderson W. Making clinical grade gene therapy vectors. Hum Gene Ther. 1994 Aug;5(8):925–926. doi: 10.1089/hum.1994.5.8-925. [DOI] [PubMed] [Google Scholar]
  7. Lincoff A. M., Topol E. J., Ellis S. G. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation. 1994 Oct;90(4):2070–2084. doi: 10.1161/01.cir.90.4.2070. [DOI] [PubMed] [Google Scholar]
  8. Mayor H. D. Defective parvoviruses may be good for your health! Prog Med Virol. 1993;40:193–205. [PubMed] [Google Scholar]
  9. Miller N., Vile R. Targeted vectors for gene therapy. FASEB J. 1995 Feb;9(2):190–199. doi: 10.1096/fasebj.9.2.7781922. [DOI] [PubMed] [Google Scholar]
  10. Mitsuka M., Nagae M., Berk B. C. Na(+)-H+ exchange inhibitors decrease neointimal formation after rat carotid injury. Effects on smooth muscle cell migration and proliferation. Circ Res. 1993 Aug;73(2):269–275. doi: 10.1161/01.res.73.2.269. [DOI] [PubMed] [Google Scholar]
  11. Nikkari S. T., Järveläinen H. T., Wight T. N., Ferguson M., Clowes A. W. Smooth muscle cell expression of extracellular matrix genes after arterial injury. Am J Pathol. 1994 Jun;144(6):1348–1356. [PMC free article] [PubMed] [Google Scholar]
  12. Rome J. J., Shayani V., Flugelman M. Y., Newman K. D., Farb A., Virmani R., Dichek D. A. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb. 1994 Jan;14(1):148–161. doi: 10.1161/01.atv.14.1.148. [DOI] [PubMed] [Google Scholar]
  13. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801–809. doi: 10.1038/362801a0. [DOI] [PubMed] [Google Scholar]
  14. Schneider M. D., French B. A. The advent of adenovirus. Gene therapy for cardiovascular disease. Circulation. 1993 Oct;88(4 Pt 1):1937–1942. doi: 10.1161/01.cir.88.4.1937. [DOI] [PubMed] [Google Scholar]
  15. Shelling A. N., Smith M. G. Targeted integration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene. Gene Ther. 1994 May;1(3):165–169. [PubMed] [Google Scholar]
  16. Wu K. K., Zoldhelyi P., Willerson J. T., Xu X. M., Loose-Mitchell D. S., Wang L. H. Gene therapy for vascular diseases. Tex Heart Inst J. 1994;21(1):98–103. [PMC free article] [PubMed] [Google Scholar]
  17. Yang Y., Nunes F. A., Berencsi K., Gönczöl E., Engelhardt J. F., Wilson J. M. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet. 1994 Jul;7(3):362–369. doi: 10.1038/ng0794-362. [DOI] [PubMed] [Google Scholar]
  18. Yu Z. X., Biro S., Fu Y. M., Sanchez J., Smale G., Sasse J., Ferrans V. J., Casscells W. Localization of basic fibroblast growth factor in bovine endothelial cells: immunohistochemical and biochemical studies. Exp Cell Res. 1993 Feb;204(2):247–259. doi: 10.1006/excr.1993.1031. [DOI] [PubMed] [Google Scholar]
  19. von der Leyen H. E., Gibbons G. H., Morishita R., Lewis N. P., Zhang L., Nakajima M., Kaneda Y., Cooke J. P., Dzau V. J. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1137–1141. doi: 10.1073/pnas.92.4.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES